Year: 2019

In Council Meeting of JSC Latvijas Gāze held on November 14, 2019, members voted that Council repeatedly will be led by Chairman Kirill Seleznev and Vice-Chairmen Juris Savickis and Oliver Giese.Further information:Esmeralda Balode-BurakaPhone: + (371) 67 374 369E-mail: investor.relations@lg.lv

UTRECHT, Pays-Bas et CAMBRIDGE, Mass., 14 nov. 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS) (« Merus », « nous », « notre/nos » ou la « Société »), une société de stade clinique qui développe des anticorps bispécifiques novateurs et pleine longueur (Biclonics®), a annoncé aujourd’hui ses résultats financiers pour le troisième trimestre clos le 30 septembre 2019 et a présenté une mise à jour de ses activités.« Nous sommes vivement encouragés par les réponses précoces récemment observées chez des patients traités avec le MCLA-128, dont les cellules tumorales hébergent une fusion NRG1, un facteur oncogène rare, et nous sommes convaincus que les données offrent une validation clinique supplémentaire de notre plateforme Biclonics® », a déclaré Ton Logtenberg, Docteur en médecine, PDG de Merus. « Nous restons concentrés sur...

UTRECHT, Niederlande und CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) ) („Merus“, „wir“, „unser“ oder das „Unternehmen“), ein Unternehmen für Immunoonkologie in der klinischen Phase, das innovative, unfragmentierte, bispezifische Antikörper (Biclonics®) entwickelt, gab heute die Finanzergebnisse für das dritte Quartal zum 30. September 2019 bekannt und legte ein Update zur Geschäftsentwicklung vor.„Wir sind sehr ermutigt von den kürzlich gemeldeten Fällen des frühen Ansprechens der Patienten, deren Tumorzellen eine NRG1-Fusion, einen seltenen onkogenen Treiber beherbergen, auf die Behandlung mit MCLA-128 und glauben, dass die Daten eine weitere klinische Validierung unserer Biclonics®-Plattform bieten“, sagte Dr. Ton Logtenberg, Präsident und Chief Executive Officer von Merus. „Wir konzentrieren uns...

WEST CALDWELL, NJ and TORONTO, ON, Nov. 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that it has initiated plans to expand its alternative insulin delivery portfolio to apply to the treatment of Alzheimer’s disease.  The initial plan is to determine the most patient-friendly and effective delivery of the company’s innovative insulin solution to treat the early onset of Alzheimer’s disease.  The company is currently evaluating its options in this proof of concept trial, which could be company sponsored or a collaboration.  The primary endpoint of Alzheimer’s disease is delaying the progression of the disease which...

New CEO Brings CBD and Manufacturing ExperienceDANA POINT, CA, Nov. 14, 2019 (GLOBE NEWSWIRE) — MC Endeavors, Inc. /Room 21 Media (PINKSHEETS: MSMY) today announced the Appointment of Steven Mazurek as new CEO and President of MC Endeavors, Inc. Given that the Company is now focused on the CBD markets, the BOD has decided it is in the Company’s and shareholder’s best interest to appoint Mr Mazurek the this position. He has the most experience, contacts and a proven track record of launching and building a successful company in the CBD industry.Mr. Stippick, former CEO states, “With Mr. Mazurek’s experience, we are looking forward to a promising new future that will begin with reporting the revenue growth in our 3rd Quarter Financials. We are now positioned for consistent increases in revenues in the CBD market space.”Management...

  JV Formed to Support Expanded Turkish Business ModelPHOENIX, AZ , Nov. 14, 2019 (GLOBE NEWSWIRE) — Taronis Technologies, Inc., (“Taronis” or “the Company”) (NASDAQ: TRNX), a leading renewable fuel producer serving the global industrial gas markets, today announced the formation of a new joint venture within the Republic of Turkey. The new Turkish company is called Taronis Fuels Turkey Gas Enerji Sanayi ve Ticaret Limited Şirketi (“Taronis Turkey”). This new entity is domiciled in Ankara, and is currently owned 74% by Taronis Fuels, Inc, and 26% by MC Consulting Teknoloji Enerji Danişmanlik Sanayi ve Ticaret Limited Şirketi (“MC Consulting”). It is expected that a third party will enter into this joint venture prior to year end, reducing Taronis Fuels stake to approximately 48%.The purpose of this new joint venture will be threefold....